Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
(Thomson Reuters ONE) -
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD)
announced that on Thursday, October 26, 2017, the Company will release financial
results for the second quarter of fiscal 2018. The Company will host a
conference call to discuss the results on Thursday, October 26, 2017, at 8:00
a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer
and Robert L. Bowen, former Chief Financial Officer, will host the conference
call.
To listen to the call live, please tune into the webcast
via http://investor.abiomed.com or dial (855) 212-2361; the international number
is (678) 809-1538. A replay of this conference call will be available beginning
at 11 a.m. EDT October 26, 2017 through 11:00 a.m. EDT on October 29, 2017. The
replay phone number is (855) 859-2056; the international number is (404)
537-3406. The replay access code is 95924236.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc. is a leading provider of medical
devices that provide circulatory support. Our products are designed to enable
the heart to rest by improving blood flow and/or performing the pumping of the
heart. For additional information, please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including statements regarding
development of Abiomed's existing and new products, the Company's progress
toward commercial growth, and future opportunities and expected regulatory
approvals. The Company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number of factors,
including uncertainties associated with development, testing and related
regulatory approvals, including the potential for future losses, complex
manufacturing, high quality requirements, dependence on limited sources of
supply, competition, technological change, government regulation, litigation
matters, future capital needs and uncertainty of additional financing, and other
risks and challenges detailed in the Company's filings with the Securities and
Exchange Commission, including the most recently filed Annual Report on Form 10-
K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue
reliance on any forward-looking statements, which speak only as of the date of
this release. The Company undertakes no obligation to publicly release the
results of any revisions to these forward-looking statements that may be made to
reflect events or circumstances that occur after the date of this release or to
reflect the occurrence of unanticipated events.
For further information, please contact:
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg(at)abiomed.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abiomed via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 563089
Anzahl Zeichen: 3423
contact information:
Town:
Danvers
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 179 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification"
steht unter der journalistisch-redaktionellen Verantwortung von
Abiomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
